A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021

Rina Sa; Yi Xu; Xinbo Pan; Yu Wang; Zhijian Lin; Xiaomeng Zhang; Bing Zhang

doi:10.3389/fonc.2023.1078254

A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021

Front Oncol. 2023 Jan 25:13:1078254. doi: 10.3389/fonc.2023.1078254. eCollection 2023.

Authors

Rina Sa^{1

2

3}, Yi Xu^{1

3}, Xinbo Pan⁴, Yu Wang^{1

3}, Zhijian Lin^{1

3}, Xiaomeng Zhang^{1

3}, Bing Zhang^{1

3}

Affiliations

¹ School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
² Department of Pharmacy, Gansu Provincial Hospital, Lanzhou, Gansu, China.
³ Center for Pharmacovigilance and Rational Use of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
⁴ Institute of liver diseases, The Second People's Hospital of Lanzhou, Lanzhou, China.

Abstract

The complexity of cancer itself and treatment makes pharmacovigilance critical in oncology. Despite rapid progress on pharmacovigilance and cancer research in the past two decades, there has been no bibliometric analysis in this field. Therefore, based on the Web of Science database, we used CiteSpace, VOS-viewer and R-bibliometrix to analyze and visualize publications, and described the development trend and research hot spots in this field. 502 publications were included. The development of pharmacovigilance and cancer research has continued to grow. The USA has the largest number of publications and citations, followed by France and UK. Vanderbilt University and Sorbonne University are the institutions that contribute the most papers, and 5 of the top 10 high-yield institutions are from France. Salem JE and Lebrun-Vignes B of Sorbonne University have published the most papers, and they have a strong cooperative relationship. Salem JE has the highest H index. Drug Safety has the largest number of publications in the field of pharmacovigilance and cancer, with a high impact factor (IF). In recent years, immune checkpoint inhibitors (ICIs) have been identified as a hot topic and will continue to be maintained. This paper can help researchers get familiar with the current situation and trend of pharmacovigilance and cancer research, and provide valuable reference for the selection of future research directions.

Keywords: bibliometric analysis; cancer; pharmacovigilance; research frontiers; visualized analysis.

Publication types

Review

Grants and funding

This work was supported by the Sub-project of Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202005-11). This study was supported by the National Natural Science Foundation of China (No.82274117 and No.82204643).